1. Change in quality of life status (change in points or percentage from baseline).

		Beebe 1999			Dawson 2000			Money 1998		O'Donnell 2009
Tool	Domain	Cilostazol 100 mg (n = 137)	Cilostazol 50 mg (n = 135)	Placebo (n = 141)	Cilostazol 100 mg (n = 205)	Pentox 400 mg (n = 212)	Placebo (n = 226	Cilostazol 100 mg (n = 119)	Placebo (n =  120)	Cilostazol 100 mg ( n = 39)	Placebo (n = 41)
Short‐form 36 (SF‐36)	Physical function	7.1	8	2	3	1.8	0.8	8.3	2.3	11%	‐0.30%
	Role‐physical	5.3	4.4	‐2.8	3.7	no improv	no improv	3.0	0.1	7.8%	5.4%
	Bodily pain	7.2	4.6	‐1.8	5.2	1.6	1.0	‐	‐	3.7%	10.5%
	Social function	1.0	0.9	0.4	no diff	no diff	no diff	‐	‐	‐	‐
	Role‐emotional	2.9	0.0	‐1.7	no diff	no diff	no diff	‐	‐	‐	‐
	Mental health	2.5	‐1.5	0.9	‐0.7	‐0.6	‐1.3	‐	‐	‐	‐
	General health	‐	‐	‐	‐	‐	‐	‐	‐	2.7%	‐1.0%
Walking Impairment Questionnaire (WIQ)	Walking speed	0.1	0.2	0.1	no diff	no diff	no diff	20.0%	0.0%	10%	4%
	Walking distance	0.2	0.2	0.1	no diff	no diff	no diff	‐	‐	‐1%	3%
Claudication Outcome Measure (COM)	Change in pain/discomfort	2.8	2.7	2.4	‐	‐	‐	‐	‐	‐	‐
	Pain/discomfort: daily activities	0.4	0.5	0.2	‐	‐	‐	‐	‐	‐	‐
	Pain/discomfort: physical activities	0.5	0.5	0.2	‐	‐	‐	‐	‐	‐	‐
	Pain/discomfort: social activities	0.3	0.4	0.3	‐	‐	‐	‐	‐	‐	‐
	Walking pain/discomfort	0.7	0.7	0.4	‐	‐	‐	‐	‐	‐	‐
	Worry/concern due to pain	0.8	0.6	0.5	‐	‐	‐	‐	‐	‐	‐
Vascular Quality of Life (VascuQol)	Activity	‐	‐	‐	‐	‐	‐	‐	‐	7.3	1.8
	Symptom	‐	‐	‐	‐	‐	‐	‐	‐	3.1	3.2
	Pain	‐	‐	‐	‐	‐	‐	‐	‐	10.4	13.2
	Emotion	‐	‐	‐	‐	‐	‐	‐	‐	5.7	1.8
	Social	‐	‐	‐	‐	‐	‐	‐	‐	1.1	3.4

diff: difference
improv: improvement
Pentox: pentoxifylline